StockData

VitaSpring Biomedical Co. Ltd. (VSBC) stock

VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31
Financials through Q2 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 17, 2026Score 4/30
$0.03+0.00 (0.00%)

Close on Oct 19, 2026Market cap $6.58MP/E –Yield –

VitaSpring Biomedical ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

VitaSpring Biomedical's ebitda for the twelve months ending Oct 31, 2025 was -$420.48K. For fiscal 2025 it was -$669.96K.

Annual ebitda

PeriodPeriod endValueChange
FY2025Jan 31, 2025-$669.96K–
FY2024Jan 31, 2024-$1.10M–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ1 2026Apr 30, 2026-$73.36K–
Q3 FY2026CQ3 2025Oct 31, 2025-$133.24K–
Q2 FY2026CQ2 2025Jul 31, 2025-$96.58K–
Q1 FY2026CQ1 2025Apr 30, 2025-$66.66K–
Q4 FY2025CQ4 2024Jan 31, 2025-$124.01K–
Q3 FY2025CQ3 2024Oct 31, 2024-$115.44K–
Q2 FY2025CQ2 2024Jul 31, 2024-$216.17K–
Q1 FY2025CQ1 2024Apr 30, 2024-$214.34K–
Q4 FY2024CQ4 2023Jan 31, 2024-$221.63K–
Q3 FY2024CQ3 2023Oct 31, 2023-$231.21K–
Q2 FY2024CQ2 2023Jul 31, 2023-$349.82K–
Q1 FY2024CQ1 2023Apr 30, 2023-$300.84K–

More VitaSpring Biomedical figures

See a number that looks wrong?